Phosphorylation of Both EGFR and ErbB2 Is a Reliable Predictor of Prostate Cancer Cell Proliferation in Response to EGF  by El Sheikh, Soha Salama et al.
Phosphorylation of Both EGFR and ErbB2 Is a Reliable Predictor
of Prostate Cancer Cell Proliferation in Response to EGF
Soha Salama El Sheikh*, Jan Domin y, Paul Abel z, Gordon Stamp* and El-Nasir Lalani*
Departments of *Histopathology, yRenal Medicine and zSurgery, Imperial College, Hammersmith
Hospital Campus, Ducane Road, London W12 0NN, UK
Abstract
Despite multiple reports of overexpression in prostate
cancer (PC), the reliance of PC cells on activated
epidermal growth factor receptor (EGFR) and its down-
stream signaling to phosphoinositide 3V-kinase/Akt
(PI3K/Akt/PTEN) and/or mitogen-activated protein
kinase (MAPK/ERK) pathways has not been fully elu-
cidated. In this study, we compared the role of EGF-
mediated signaling in nonmalignant (BPH-1, PNT1A,
and PNT1B) and PC cell lines (DU145, PC3, LNCaP, and
CWR22Rv1). EGF-induced proliferation was observed
in all EGFR-expressing PC cells except PC3, indicating
that EGFR expression does not unequivocally trigger
proliferation following EGF stimulation. ErbB2 recruit-
ment potentiated EGF-induced signals and was asso-
ciated with the most pronounced effects of EGF
despite low EGFR expression. In this way, the sum of
EGFR and ErbB2 receptor phosphorylation proved to
be a more sensitive indicator of EGF-induced pro-
liferation than quantification of the expression of
either receptor alone. Both Akt and ERK were rapidly
phosphorylated in response to EGF, with ERK phos-
phorylation being weakest in PC3 cells. Extrapolation
of these findings to clinical PC suggests that assess-
ment of phosphorylated EGFR + ErbB2 together
could serve as a marker for sensitivity to anti-EGFR–
targeted therapies.
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Introduction
Growth factors and their receptors have received much
attention as potential targets for the treatment of prostate
cancer (PC) [1,2]. Epidermal growth factor (EGF) and the re-
lated transforming growth factor-a (TGF-a) are two auto-
crine/paracrine growth factors that have been identified in
PC specimens and cell lines (reviewed in Refs. [3,4]). Their
cognate receptor, the epidermal growth factor receptor
(EGFR/ErbB1), is the most extensively studied member of
the ErbB family, which includes ErbB2 (HER-2/Neu) [5],
ErbB3 (HER-3) [6], and ErbB4 (HER-4) [7]. Many cells
coexpress multiple ErbB receptors that homodimerize
and heterodimerize upon stimulation with growth factor
ligands [8].
Activated ErbB receptors trigger a number of important
intracellular signaling pathways, including the phosphoinositide
3V-kinase (PI3K) and mitogen-activated protein kinase/extra-
cellular-related kinase 1/2 (MAPK/ERK1/2) pathways. Class IA
PI3K is recruited through an 85-kDa adapter subunit to phos-
photyrosine residues on cytoplasmic domains of activated
ErbB receptors [9], particularly ErbB3 [10]. The recently iden-
tified class II PI3K enzymes also lie downstream of EGFR,
where they bind adaptor proteins through proline-rich regions
present within their N-terminal sequences [11,12]. The 3V-
phosphoinositide (PtdIns) products of class I and class II
PI3K activity act as membrane-associated secondmessengers
that bind and recruit a variety of cytosolic signaling enzymes
to the cell membrane [9]. One of these, the serine/threonine
kinase Akt, becomes phosphorylated at Thr308 and Ser473
residues, and promotes survival through multiple mechanisms
[13]. PTEN (phosphatase and tensin homologue deleted on
chromosome 10) is a tumor-suppressor gene that downregu-
lates Akt activity by acting as a PtdIns (3,4,5) P3 3-phospha-
tase [14]. The phosphorylation status of Akt (P-Akt) in vitro and
in vivo has been widely used to monitor aspects of malig-
nant behavior such as proliferation, resistance to chemother-
apy, irradiation, invasion, and metastasis [15,16].
The MAPK cascade constitutes a functional signaling unit
that links surface receptor–mediated signals to nuclear events
affecting cellular processes of growth, division, differentiation,
and death [17]. Phosphorylation of the most downstream
elements, p44 and p42 MAPKs (also called ERK1 and
ERK2), is a hallmark of MAPK activation and is increased in
many human tumors including PC [18,19].
With the advent of novel therapies that specifically target
ErbB receptors, there is a need to establish rational methods
to stratify tumors that are dependent on these receptors for
growth and survival. This would allow selective targeting of
patients whose tumors were most sensitive, and identify those
who might be resistant to these treatments. In this report, we
used immortalized nonmalignant prostatic cells (BPH-1,
PNT1A, and PNT1B) and PC cell lines (CWR22Rv1, LNCaP,
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DU145, and PC3) to identify molecular markers that would
correlate best with an EGF-induced proliferative response.
We compared cell proliferation, ErbB/PI3K/Akt/PTEN ex-
pression, ErbB receptor phosphorylation, PI3K/Akt, and
MAPK enzyme activation in these cells under basal condi-
tions and with EGF stimulation to ascertain potential differ-
ences between responsive and nonresponsive cells.
Materials and Methods
Cell Culture
BPH-1 [20], PNT1A, and PNT1B [21,22] were gifts from
Dr. S. Hayward (Vanderbilt University School of Medicine)
and Prof. N. Maitland (York, UK), respectively. PC cell lines
CWR22Rv1 [23], LNCaP [24], DU145 [25], and PC3 [26]
were obtained from the American Type Culture Collection
(ATCC; Rockville, MD). BPH-1, PC3, LNCaP, and
CWR22Rv1 cells were routinely maintained in RPMI 1640,
whereas PNT1A, PNT1B, and DU145 were maintained in
Dulbecco’s modified Eagle’s medium (DMEM). Media were
supplemented with 10% fetal bovine serum (FBS) and
cultures were grown at 37jC and 10% CO2.
Reagents and Antibodies
FBS was obtained from Gibco Europe Ltd. (Paisley, Scot-
land, UK). RPMI 1640 and DMEM culture media were
obtained from Cancer Research UK (CRUK, London, UK).
Recombinant human EGF was obtained from Peprotech
(London, UK). The PI3K inhibitor, wortmannin, was pur-
chased from Sigma-Aldrich Company Ltd. (Dorset, UK) and
LY294002 from Calbiochem (CN Biosciences, Nottingham,
UK). Antibodies to EGFR (sc-03),PTEN (sc-7974), andPY99
(sc-7020) were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Antibodies to c-ErbB2 (Ab-17), c-ErbB3
(Ab-7), and c-ErbB4 (Ab-4) were obtained from Neomarkers
(Fremont, CA). Antibodies to EGFR (Ab-1 Mab-528) and
c-ErbB4 (Ab-1) were obtained from Oncogene (Nottingham,
UK). Anti-PI3K antibody (anti-p85) and antiphosphotyrosine
antibody PY20 (610000) were obtained from BD Biosciences
(Lexington, KY). Total Akt (9272) and Ser473-Akt (9271)
were obtained from New England Biolaboratories (Beverly,
MA). The PI3K-C2a and PI3K-C2b antisera were previously
characterized [11,27]. Anti–phospho-MAPK was obtained
from Promega (Southampton, UK). b-Actin antibody was
obtained from Sigma-Aldrich Company Ltd.
Cell Proliferation Assay
Cells were dispersed by trypsin–EDTA, resuspended in
serum-supplemented medium, and seeded into 24-well cul-
ture plates at a density of 5  103 cells/ml. Following an
overnight incubation, cells were washed and treated with
serum-free medium for 24 hours. At the end of this time, cells
were either treated with fresh serum-free medium (control),
or EGF was applied at ascending concentrations of (0.01–
10 ng/ml) (day 0). Cell growth was monitored either by: 1)
adding alamarBlue (Biosource, Nivelles, Belgium) at a con-
centration of 10% on day 0, assessed daily for the reduced
product by reading fluorescence (Cytoflour2300; Millipore,
Watford, UK) (emission filter 530; excitation filter 590); or 2)
counting the cell number in triplicate cultures daily using a
Coulter Counter (Luton, UK).
Western Blot (WB) Analysis and Immunoprecipitation (IP)
Asynchronous cultures were lysed in Triton X-100 lysis
buffer (10 mM Tris–HCl, pH 7.6, 5 mM EDTA, 50 mM NaCl,
30 mM sodium pyrophosphate, 50 mM NaF, 100 mM
Na3VO4, and 1% Triton X-100) supplemented with protease
inhibitors [5 mg/ml aprotinin, 1 mM pepstatin, 1 mg/ml anti-
pain, 1 ng/ml leupeptin, and 100 mM phenylmethylsulfonyl
fluoride (PMSF)] at 4jC for 20 minutes. Alternatively, cul-
tures were serum-starved overnight then stimulated with
EGF (100 ng/ml) for 10 minutes at 37jC, or pretreated with
wortmannin (50 nM) then lysed as described above. Lysates
were clarified by centrifugation (13,000g for 20 minutes at
4jC). Protein samples were either fractionated directly or
immunoprecipitated for 3 hours at 4jC. Immune complexes
were collected on protein A Sepharose beads for 1 hour
(Amersham Pharmacia Biotechnology, Buckinghamshire,
UK), washed in lysis buffer, and extracted in sample buffer
[200 mM Tris–HCl, 6% sodium dodecyl sulfate (SDS), 2 mM
EDTA, 4% 2-mercaptoethanol, 10% glycerol, pH 6.8] then
fractionated in an 8% to 10% gel. Proteins were electro-
transferred to polyvinylidene difluoride (PVDF) membranes
and Western-blotted with the optimally diluted primary anti-
bodies. Horseradish peroxidase (HRP)–conjugated second-
ary antibodies (sheep antimouse/donkey antirabbit)
(Amersham Pharmacia Biotechnology) and enhanced
chemiluminescence (ECL; Amersham Pharmacia Biotech-
nology) were used to visualize immunoreactive proteins.
Densitometric analysis of optimally exposed radiographic
film using a high-resolution scanner and the UN-SCAN-IT
gel analysis software (Version 5.1; Silk Scientific, Inc., Orem,
UT) was used to quantify the relative band intensities.
Results were expressed as average pixel values.
Statistical Analysis
Cell proliferation data were statistically analyzed using
Student’s t test. A value of P < .05 was considered as
statistically significant. The GraphPad Prism statistical pack-
age was used to perform the analysis (version 3.02 for
Windows; GraphPad Software, San Diego, CA).
Results
EGF-Induced Cell Proliferation
The difficulty in establishing primary PC cell lines from
explants of prostate tissues has resulted in a scarcity of PC
cell lines compared to the clinical prevalence of PC or the
number of cell lines available for other solid tumors [23]. Our
initial assessment of the effect of EGF on PC cell proliferation
involved treatment of four widely available PC cell lines
DU145, CWR22Rv1, LNCaP, and PC3 with ascending
doses of EGF, and monitoring their proliferation over a 5-
day period using alamarBlue assay. Addition of EGF (1–10
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ng/ml) increased the proliferation of LNCaP, CWR22Rv1,
and DU145 cells compared to untreated cells (Figure 1). This
effect was observed earlier and at lower doses of EGF (0.1–
10 ng/ml) in LNCaP cells. It was least notable in DU145 cells
where an EGF-induced growth response was observed after
3 days of treatment with 10 ng/ml EGF compared to untreat-
ed cells. Growth of PC3 cells treated with up to 10 ng/ml EGF
did not show any increase above the control. To confirm
these observations and to analyze the effects of EGF on
immortalized cell lines, cultures were treated with a concen-
tration of 10 ng/ml EGF for 96 hours followed by trypsiniza-
tion and counting. A significant increase in cell number was
observed in BPH-1 (P = .01), DU145 (P = .01), LNCaP (P <
.001), and CWR22Rv1 (P < .001), but not in PNT1A, PNT1B,
or PC3 cells (P = 0.62, P = .45 and P = .386, respectively)
(Figure 2). The greatest change in EGF-induced proliferation
was seen in the LNCaP cells where proliferation nearly
doubled compared to control.
Expression of ErbB Receptors in PC Cell Lines
We then explored the relationship between EGF-induced
mitogenesis and levels of ErbB receptor expressed as
analyzed by Western blot analysis. Of the immortalized cell
lines, only BPH-1 cells expressed high levels of EGFR. All
expressed low levels of ErbB2 but none expressed ErbB3
or ErbB4 (Figure 3). Of the PC cell lines, only CWR22Rv1
expressed all four ErbB receptors, whereas LNCaP, DU145,
and PC3 expressed EGFR, ErbB2, and ErbB3 but not
ErbB4. Regarding ErbB3, high levels were observed in
DU145 and CWR22Rv1 cells with markedly lower levels in
Figure 1. Growth curve of PC cells following EGF stimulation. Serum-starved cultures incubated in the absence (-.-) or presence of ascending concentrations of
EGF (-o-, 0.01 ng/ml; -E-, 0.1 ng/ml; --, 1 ng/ml; -5-, 10 ng/ml) were monitored daily by fluorometric measurement of the rate of reduction of alamarBlue for 5
days following treatment. Error bars represent standard error of the mean.
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PC3 and LNCaP (Figure 3). These data are consistent with
our observation that EGF-induced proliferation only occurred
in cells that express EGFR. Surprisingly, cellular levels of
EGFR did not predict the magnitude of the proliferative
response. For example, PC3 cells expressed more EGFR
than LNCaP, and yet no difference in proliferation was
observed between PC3 cells grown in the presence or
absence of EGF. The data also indicate that high ErbB2
expression is not required for EGF-induced mitogenesis
because BPH-1 cells, which expressed low levels of ErbB2,
proliferated in response to EGF treatment (Figure 2).
EGF-Induced Receptor Dimerization and Phosphorylation
To identify indicators, besides the expression of EGFR
that could favor the proliferation of one PC line and not
another, we analyzed the degree of ErbB receptor dimeriza-
tion and phosphorylation following EGF stimulation. Quies-
cent EGFR-expressing prostatic cells were stimulated with
EGF, lysed, and immunoprecipitated using antibodies to
EGFR, ErbB2, ErbB3, ErbB4, or antiphosphotyrosine
(PY20) (Figure 4). Following EGF stimulation, EGFR be-
came phosphorylated in each cell line. EGF-induced hetero-
dimerization of EGFR and ErbB2 was consistently observed.
Levels of phosphorylated ErbB2 were higher in LNCaP cells
than those typically seen in other PC cell lines (data for
CWR22Rv1 and LNCaP are shown in Figure 4). Unlike
EGFR and ErbB2, no detectable levels of ErbB3 and ErbB4
tyrosine phosphorylation were observed under experimental
conditions used in this study. In this way, ErbB3 and ErbB4
do not appear to be significant dimerization partners of the
EGFR in prostatic cells.
To compare receptor-mediated tyrosine phosphorylation
across the different cell lines, EGF-stimulated cells (3  106
cells/ml) were lysed, immunoprecipitated, then Western-
blotted using an antiphosphotyrosine antibody (Figure 5A).
EGF had no effect on PNT1A cells (data not shown) but
rapidly increased tyrosine phosphorylation of several pro-
teins, most prominently those corresponding to the ErbB
receptors (170–185 kDa). This phosphorylation was highest
in BPH-1 and LNCaP, followed by DU145, and lowest in PC3
cells. Under starved conditions, an elevated phosphotyro-
sine content in BPH-1 and DU145 cells indicated that these
cells were perhaps not rendered completely quiescent.
To evaluate the relative amounts of tyrosine-phosphoryl-
ated EGFR and ErbB2 incorporated within this phosphotyr-
osine immune complex, the blot was reprobed for each
receptor (Figure 5, B and C) and the data were scanned
and quantified (Figure 5D). Marked EGFR phosphorylation
was observed in BPH-1, whereas EGFR/ErbB2 heterodime-
rization was evident in DU145, LNCaP, and CWR22Rv1
cells. In PC3 cell lysates, EGFR and ErbB2 were hardly
detectable in antiphosphotyrosine immunoprecipitates.
Quantitatively, the total amount of phosphorylated EGFR +
ErbB2 was highest in EGF-responsive cells. The values
obtained with PC3 cells were at least less than one third of
those seen with other cells. These data indicate that relative
expression levels of EGFR do not correlate with the degree
to which the individual ErbB receptors are activated in
response to EGF, and that the sum of phosphorylated EGFR
and phosphorylated ErbB2 is a more sensitive indicator of
EGF-induced proliferation than total levels of EGFR
expressed.
Expression and Activation of PI3K/Akt in PC Cell Lines
We first evaluated the expression of the class IA adaptor
p85 and class II PI3K enzymes (PI3K-C2a and PI3K-C2b),
Akt and PTEN. We observed that p85, PI3K-C2a, PI3K-C2b,
and Akt were each expressed in all seven cell lines in
equivalent amounts (Figure 6). PTEN was expressed in
all cells except LNCaP and PC3. Reverse transcription
Figure 2. EGF-induced cell proliferation in prostate cell lines. Cells were
serum-starved for 24 hours then treated with fresh serum-free medium or 10
ng/ml EGF. Cells were trypsinized and counted after 4 days of treatment.
Changes in cell number in response to EGF were represented as fold
increase over control. A two-fold change in cell number equals 2.0 fractional
change, whereas 1 represents identity with control cells. Data obtained from
three experiments are represented as mean with error bars representing
standard error of the mean. *P < .05 was considered significant.
Figure 3. Expression of ErbB receptors in prostate cell lines. Protein lysates
from an equal number of cells were fractionated by SDS polyacrylamide gel
electrophoresis (PAGE) and Western-blotted with indicated antibodies.
Proteins were visualized with HRP-labeled secondary antibody and ECL
detection. Equal loading was confirmed by blotting for -actin.
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polymerase chain reaction (RT-PCR) and sequence analysis
confirmed the expression of wild-type PTEN mRNA in BPH-
1, PNT1A, PNT1B, DU145, and CWR22Rv1, and the previ-
ously reported PTEN mutation/deletion in LNCaP and PC3
cells [28,29] (data not shown).
To confirm that Akt activation is dependent on PI3K-
generated phosphoinositides, we treated PTEN-expressing
prostatic cell lines (BPH-1, PNT1A, DU145, and CWR22Rv1)
with the PI3K inhibitor, wortmannin. Cultures were stimulated
with EGF, and Akt phosphorylation was quantified in the
resultant lysates using an anti–phospho-Ser473 Akt anti-
body. Wortmannin attenuated or abolished Akt phosphoryl-
ation when added simultaneously with or prior to EGF,
respectively (Figure 7A). PNT1A cells, which do not express
EGFR, showed no Akt phosphorylation in response to EGF
(data not shown). This confirms that EGF-induced Akt phos-
phorylation is dependent on EGFR expression and PI3K
activation in these cells.
She et al. [30] have recently reported that loss of PTEN
function and overactive phosphoinositide signaling
uncoupled EGFR and PI3K/Akt signaling pathways, making
cells insensitive to extracellular stimuli. They also suggested
that PI3K inhibition reestablishes EGFR-stimulated Akt acti-
vation by reducing constitutive basal activation of Akt. In
PTEN-null PC3 and LNCaP cells, Akt phosphorylation was
elevated under serum-starved (basal) conditions compared
to PTEN-expressing CWR22Rv1 cells (Figure 7B). However,
contrary to that study [30], wortmannin reduced constitutive
Akt phosphorylation in LNCaP and PC3 cells and rendered
them insensitive to further EGF stimulation similar to PTEN-
expressing CWR22Rv1 cells. Another PI3K inhibitor,
LY294002, also reduced Akt phosphorylation in a dose-
dependent manner in LNCaP cells (Figure 7C). Taken
together, these findings indicate that phosphorylated Akt is
a robust indicator of PI3K activation in both PTEN-positive
and PTEN-null PC cells.
We then analyzed the impact of ErbB expression and
phosphorylation on PI3K/Akt activation. Despite variations
in EGFR and PTEN expression, Akt phosphorylation in re-
sponse to EGF (Figure 7D) was increased in each cell line
compared to control cells, including PC3 cells, which do not
proliferate in response to EGF. Cells that expressed more
ErbB3 (CWR22Rv1 and DU145) did not show higher
Akt phosphorylation compared to cells with lower ErbB3
Figure 4. EGF induces ErbB receptor phosphorylation. CWR22Rv1 (panel A)
cells and (panel B) LNCaP cells were incubated in serum- free medium
overnight then stimulated with 100 ng/ml EGF for 10 minutes at 37C. Cell
lysates were prepared with protein A Sepharose beads in the absence () or
presence of ErbB antibodies or PY20. The resultant immune complexes were
fractionated by SDS-PAGE and Western-blotted. The pattern of ErbB
phosphorylation shown in CWR22Rv1 (panel A) was typical of that seen in
other EGFR-expressing PC cell lines (except LNCaP cells).
Figure 5. EGF induces strong tyrosine phosphorylation in responsive
prostatic cells. Panel A: Confluent cultures of prostatic cells were serum-
starved overnight then incubated in the absence () or presence (+) of EGF
(100 ng/ml) for 10 minutes before lysates were prepared. These were
immunoprecipitated with antiphosphotyrosine antibody (PY20) and the
resultant immune complexes were fractionated by SDS-PAGE and West-
ern-blotted using the antiphosphotyrosine antibody (PY99), EGFR (panel B),
and ErbB2 (panel C). Radiographs shown in panels B and C were scanned
and digitalized to semiquantify EGFR and ErbB2 phosphorylation (panel D).
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expression (LNCaP and PC3). Taken together, our data
indicate that the degree to which EGF stimulates the PI3K/
Akt pathway is similar in prostate cell lines that expressEGFR
regardless of their derivation (i.e., immortalized or PC), level
of either EGFR or ErbB3 expression, amplitude of EGF-
induced ErbB phosphorylation, and the presence or absence
of a functional PTEN.
p42/p44 MAPK Activation Correlates with ErbB Receptor
Phosphorylation in PC Cells
From the above experiments, it became clear that early
events of signal transduction (i.e., differences in ErbB re-
ceptor expression, phosphorylation, and dimerization) were
more relevant physiologically to EGF-induced proliferative
responses than PI3K/Akt activation. To analyze the role of an
alternative signaling cascade, the MAPK pathway was ex-
amined using the phosphorylation of ERK as readout. PC
cells were incubated in serum-free medium overnight before
stimulation with EGF. Cells were then lysed, and proteins
were fractionated and Western-blotted using an antibody
against phosphorylated—and thus active—forms of MAPK/
ERK1/2 (p44/p42). Consistent with a previous report [31],
DU145 cells exhibited high basal ERK phosphorylation,
which was not reduced by 24-hour serum withdrawal. EGF
stimulation rapidly increased ERK phosphorylation in all PC
cells compared to control cultures. This increase was more
evident in DU145, CWR22Rv1, and LNCaP cells compared
to PC3 cells, where phosphorylation was weaker, especially
ERK2 (p42) (Figure 7D).
Discussion
Over the last decade, data have accumulated to suggest that
aberrant expression of EGFR and ErbB2 was involved in the
development of PC [32–37]. Although providing important
prognostic information, these immunohistochemical studies
often examine the expression of a single receptor and
neglect the fact that up to four ErbB receptors could play a
role in transducing the signaling response. They also do not
address the influence of ErbB receptor expression/coexpres-
sion on the cellular response to a growth factor such as EGF
and on downstream signaling pathways. In vitro models,
which reflect the heterogeneity of PC in the clinical setting,
have allowed us the opportunity to correlate cellular growth
kinetics with specific activated biochemical pathways.
Consistent with the aforementioned reports, EGFR,
ErbB2, and also ErbB3 were frequently coexpressed in PC
cell lines compared to nonmalignant cells. Immortalized
nonmalignant prostatic cell lines (BPH1 and PNT1A/PNT1B)
may generally be considered equivalent to prostatic intra-
epithelial neoplasia, which could progress to PC under
certain conditions [38]. PNT1A and PNT1B cells are thought
to be derived from luminal prostatic epithelium [22] and were
found to be EGFR-negative and insensitive to EGF stimula-
tion. BPH-1 cells were originally reported to be of similar
derivation, but they were found to express basal cell markers
including EGFR (this report) and cytokeratin 14 [39]. This
suggests that BPH-1 cells are derived from either basal or
intermediate prostatic cells. Their strong EGF-induced
responses could contribute to their transformation/malignant
Figure 6. Expression of PI3K/Akt/PTEN in prostate cell lines. Protein lysates
from an equal number of cells were fractionated by SDS-PAGE and Western-
blotted with indicated antibodies. Proteins were visualized with HRP-labeled
secondary antibody and ECL detection. Equal loading was confirmed by
blotting for -actin.
Figure 7. Inhibition of PI3K/Akt signals in prostate cell lines. Panels A and B:
Indicated cells were serum-starved overnight then incubated with medium ()
or wortmannin (W) (50 nM) for 20 minutes followed by EGF (E) or EGF +
more wortmannin (EW). Lysates from stimulated cells were included as a
positive control (P). Panel C LNCaP cells were treated with indicated doses of
LY294002 followed by EGF stimulation (10 ng/ml). Wortmannin and
LY294002 reduced Akt phosphorylation but had no effect on total Akt
expression levels. Panel D: PC cells were serum-starved overnight then
incubated in the absence () or presence of 10 ng/ml EGF (E) for 10 minutes
at 37C. Lysates were probed for phosphorylated Akt, phosphorylated MAPK/
ERK, and -actin as a loading control.
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potential, which was demonstrated on exposure to carcino-
genic doses of testosterone and estradiol or in PC-associat-
ed fibroblast coculture [38].
The relative abundance of ErbB receptors within a given
cell type is likely to influence the nature and intensity of
growth factor– induced signals and the signaling cascades
they initiate. EGF was a mitogen for all prostatic cell lines
(nonmalignant or malignant) that express EGFR with the
exception of PC3 cells. The expression of either EGFR or
ErbB2 alone failed to predict the magnitude of EGF-induced
mitogenic responses, ErbB phosphorylation, or the degree of
PI3K/Akt or MAPK activation. Tyrosine phosphorylation in
serum-starved DU145 and BPH-1 cells may result from
autocrine production of either TGF-a or EGF [40–42].
Equivalent levels of PI3K/Akt expression in prostatic cells
(whether of benign or malignant origin) and loss of PTEN
expression in two of four malignant PC cell lines suggest that
the increased activity, rather than overexpression, of PI3K/
Akt enzymes is important in PC development. Cells with an
intact PTEN expressed higher levels of EGFR and ErbB3
than those with mutated PTEN, but when deprived of serum,
the latter expressed increased levels of phosphorylated Akt.
This suggests that, if PTEN is intact, elevated expression of
the ErbB receptors alone is insufficient to activate the PI3K/
Akt pathway under basal conditions. The absence of PTEN
activity did not preclude a rise in Akt phosphorylation follow-
ing stimulation. These findings denote that PTEN is the
critical regulator of phosphorylated Akt under basal condi-
tions. In cells lacking PTEN, other mechanisms (including
other phosphoinositide 3V-phosphatases) [43–45] may be
involved in downregulating acutely elevated PtdIns levels to
allow signal amplification and propagation in response to
new exogenous stimuli.
In PC3 cells, both Akt and MAPK were rapidly activated in
spite of a low EGF-induced tyrosine phosphorylation. The
absence of functional PTEN could allow phosphoinositide
products of PI3K to accumulate after EGF stimulation and to
amplify Akt phosphorylation signals. However, this was
insufficient to drive PC3 cells into mitosis because they did
not proliferate in response to EGF treatment. On the other
hand, greater phosphorylation of ERK was observed in
LNCaP cells, which are also PTEN-null but do proliferate in
the presence of EGF. Activation of the MAPK pathway thus
correlated well with EGF-induced phosphotyrosine and mi-
togenic responses in PC cells. If PTEN-null, phosphorylation
of ERK becomes a more reliable marker of proliferative
potential than Akt phosphorylation in these cells.
Establishing the relative contribution of individual mem-
bers of the ErbB receptor family and activated downstream
pathways in PC proliferation is far from complete. Our data
support previous in vivo observations of upregulated expres-
sion of ErbB receptors in PC compared to nonmalignant
prostate cells. They also suggest that, with appropriate
controls, quantifying the sum of EGFR and ErbB2 phospho-
rylation could identify those PCs that grow in response to
EGF and are likely to benefit from anti-EGFR–directed
therapies. More work is required to assess the utility of
quantifying receptor expression ratios and to establish stand-
ards and limits that associate ErbB receptor phosphorylation
with mitogenesis.
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